Long-term studies of effects fo methionyl-human growth hormone in Hypopituitary patients
| Autor: | M Gusiñe, E Vicens-Calvet, Laura Audí, J M Cuatrecasas, Neus Potau, B Strindberg, M Albisu, Antonio Carrascosa |
|---|---|
| Rok vydání: | 1984 |
| Předmět: |
medicine.medical_specialty
biology business.industry Growth hormone medicine.disease Somatomedin Methionyl human growth hormone Growth hormone deficiency Growth velocity Titer Basal (phylogenetics) Endocrinology Internal medicine Pediatrics Perinatology and Child Health medicine biology.protein Antibody business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Pediatric Research. 18:1216-1216 |
| ISSN: | 1530-0447 0031-3998 |
| DOI: | 10.1203/00006450-198411000-00095 |
| Popis: | Ten children with growth hormone deficiency (GHD), were included in a clinical trial with methionyl-human growth hormone (M-hGH). Six of them (A) previously treated with human growth hormone (hGH) were switched to a 9 months double-blind study with the same dosage (4 I.U./3 times a week) of M-hGH or hGH and the four new cases (B) received an equal dosage of M-hGH for 6-9 months. The patients were clinically controlled every 3 months. Growth hormone antibody titre (GHA) was determined every 1 1/2 months and bioassayable somatomedin (BSM), somatomedin C (SMC) and other biochemical parameters every 3 months. Results : 1- Growth velocity was maintained at previous values in A in all cases and in B a clear catch-up was observed. 2- Both treatments normalized BSM levels throughout the study but wide variations in SMC were observed. 3- Antibody titre was positive at 3-6 months in the majority of cases treated with M-hGH, with a progressive increase of GH basal levels. In conclusion : M-hGH induces generation of BSM and promotes growth in GHD, but more prolonged study on the characterization and possible side-effects of GHA is required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|